| Name | Title | Contact Details |
|---|
ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.
Cerus Corporation is dedicated solely to safeguarding the world`s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
Founded in 2017, Unlearn.AI brings together a world-class team of experts across pharma, physics, machine learning, and business who share a vision of pioneering AI to eliminate trial and error in medicine. Unlearn is the only company creating TwinRCTsTM, which combine AI, prognostic digital twins, and novel statistical methods to run clinical trials requiring fewer patients in the control arm. Unlearn`s technology is used by leading global pharmaceutical companies, including Merck KGaA, Darmstadt, Germany, and has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics. The European Medicines Agency qualifies Unlearn`s PROCOVA™ procedure, which provides the regulatory framework for the application of TwinRCTs to Phase 2 and 3 clinical trials.
Welcome to Redpin Therapeutics. We are a privately held, preclinical stage gene therapy company based in New York City. We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage`s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage`s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.